| |
| 2007 |
| |
 |
February 12, 2007 |
| |
The Patent Attack |
| |
India’s patent law is under the scanner after Novartis challenged it in court and the Mashelkar Committee found fault with it. But the domestic drugs industry is fighting back with global support |
|
| |
|
January 15, 2007 |
| |
The Makeover |
| |
Jubilant Biosys is trying to transform itself into a drug discovery services company, while strengthening its roots in bioinformatics |
|
| |
|
January 08, 2007 |
| |
Dark Horses |
| |
Ratan Tata and Big Pharma Merck have bet early on these men. Now Advinus Therapeutics, their brainchild, has to deliver |
|
| |
| 2006 |
| |
|
December 18, 2006 |
| |
Healthcare: The Corporate Push |
| |
Following pioneer Apollo, now Max, Fortis and Wockhardt are adding a new dimension to the private hospital industry |
|
| |
|
December 04, 2006 |
| |
Bucking the Trend |
| |
Indian pharma outsourcing companies are buying up high cost operations in the West. Is this a sound strategy? |
|
| |
|
November 20, 2006 |
| |
The New Drug Chain |
| |
Indian and small western companies are together creating a drug discovery ecosystem that can challenge the might of the Big Pharma one day |
|
| |
|
September 11, 2006 |
| |
The Matrix Revolution |
| |
In 2000, N. Prasad bought a company for Rs 3 crore. In August 2006, he sold it for a valuation of Rs 6,210 crore |
|
| |
|
| |
|
July 17, 2006 |
| |
Biogenerics |
| |
Indian Pharma’s Big Opportunity |
|
| |
|
| |
|
May 15, 2006 |
| |
Cracking the Generic Code |
| |
Ranbaxy and Dr. Reddy’s are getting their strategy right to capture the $50-billion US generic market |
|
| |
|
April 03, 2006 |
| |
Dr Reddy's Polypill: Blockbuster or Dud? |
| |
Hyderabad-based company is racing to become the first pharma company in the world to introduce the controversial multiple-product pill for heart ailments |
|
| |
|
March 20, 2006
|
| |
Eurocentric! |
| |
Dr Reddy's Labs has firmed up its European foray with the purchase of German generic company betapharm for $570 million |
|
| |
|
February 06, 2006 |
| |
Basking in the Rising Sun |
| |
Call him Mr Conservative or Mr Pragmatist, chairman Dilip Shangvi's strategy has made Sun Pharma the shining star in the industry. But can he sustain the growth tempo? |
|
| |
|
January 23, 2006 |
| |
On the Discovery Trail |
| |
G.V. Sanjay Reddy and D.S. Brar of GVK Biosciences are among the first to tap the hot opportunity in drug discovery services |
|
| |
| |
2005 |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
October 10, 2005 |
| |
Neglected Diseases: Vital Signs |
| |
Can vaccines and drugs for diseases like malaria and tuberculosis become the next profit-spinners for Indian pharma? |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
| |
2004 |
| |
|
|
| |
|
| |
|
November 01, 2004 |
| |
Is the Pharma Dream Run Over? |
| |
A series of events threaten to scuttle Indian pharma majors' well-laid plans for the US generics market |
|
| |
|
August 16, 2004 |
| |
The Battle for Delhi |
| |
Four years after its grand plans for Delhi, Fortis has had a reality check. Can Shivinder Mohan's new battle plan win the market? |
|
| |
|
July 19, 2004 |
| |
Wockhardt's Human Insulin |
| |
Notching up gains in the Rs 211-crore human insulin market is proving to be an uphill battle for the Indian drug maker |
|
| |
|
July 12, 2004 |
| |
Morale Booster, Yes; Profit Booster, No |
| |
The recently-published clinical study of ragaglitazar is a tremendous psychological boost to the drug discovery programme of Dr. Reddy's Laboratories |
|
| |
|
| |
|
July 12, 2004 |
| |
Pathology Labs: Looking for Growth Options  |
| |
Six players have emerged clear winners from the first wave of corporatisation. But starved of options in an increasingly unruly market, they are again on the lookout for ways to grow |
|
| |
|
June 28, 2004
|
| |
What's the Big Deal? |
| |
Most overseas acquisitions by Indian pharma firms amount to small change from a global perspective. Shouldn't it be betting bigger? |
|
| |
|
June 14, 2004
|
| |
Prospect Next |
| |
A crop of Indian companies is readily converting the opportunity presented by outsourced work in pharma. A look at the different segments in which the prospects lie |
|
| |
|
| |
|
May 24, 2004 |
| |
The $20 Billion Pills |
| |
A few Indian generics makers want a swipe at the western statin market. Will they succeed? |
|
| |
|
March 15, 2004
|
| |
Sunny Side Up |
| |
Dilip Shanghvi's global plans for Sun Pharma hit an unexpected speedbreaker in Caraco. But the entrepreneur appears to have emerged stronger from the crisis |
|
| |
| |
2003 |
| |
|
|
December 22, 2003 |
| |
The Health Travellers |
| |
The market is $40 billion and counting. It is growing at 20% every year. But how does one tap the opportunity? |
|
| |
|
| |
| |
September 29, 2003 |
|
Brar's Ranbaxy |
| |
One man's 10-year journey in search of the holy grail: an Indian multinational. What he found, how, and what he intends to do now |
|
| |
